CONDUIT PHARMACEUTICALS INC. Quarterly Operating Income (Loss) in USD from Q4 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Conduit Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2021 to Q3 2024.
  • Conduit Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$5.81M, a 1251% decline year-over-year.
  • Conduit Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$14.3M, a 217% decline year-over-year.
  • Conduit Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$5.26M, a 66.5% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$14.3M -$5.81M -$5.38M -1251% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$8.95M -$3.14M -$2.25M -254% Apr 1, 2024 Jun 30, 2024 10-Q/A 2024-11-14
Q1 2024 -$6.7M -$2.96M -$1.44M -95.1% Jan 1, 2024 Mar 31, 2024 10-Q/A 2024-11-14
Q4 2023 -$5.26M -$2.43M -$745K -44.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-16
Q3 2023 -$4.52M -$430K +$503K +53.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$5.02M -$888K -$609K -218% Apr 1, 2023 Jun 30, 2023 10-Q/A 2024-11-14
Q1 2023 -$4.41M -$1.52M -$1.25M -474% Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-11-14
Q4 2022 -$3.16M -$1.68M -$1.68M -38336% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-16
Q3 2022 -$1.48M -$933K Jul 1, 2022 Sep 30, 2022 10-Q/A 2023-11-21
Q2 2022 -$279K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$264K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$4.38K Oct 19, 2021 Dec 31, 2021 10-K 2023-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.